The U.S. pharmaceutical industry is in the middle of the largest domestic manufacturing buildout in its history. Since early 2025, drug companies have announced more than $480 billion in U.S. manufacturing investment commitments, according to research published by Think Global Health in November 2025. AstraZeneca pledged $50 billion. Johnson & Johnson committed $55 billion. Eli Lilly’s combined investment plan now exceeds $50 billion across multiple facilities.
The capital is real. The press releases are constant. The factories are being built.
And most of them will not run at full capacity on schedule, because the people who would operate them do not exist yet.
This is the part of the story pharma manufacturing leaders keep missing.
Global Location Strategies, a corporate site selection firm, published its 2026 Best Places for Pharmaceutical Manufacturing Insights Report in October 2025. The headline finding was direct: the $350 billion investment boom currently underway in U.S. pharmaceutical manufacturing is constrained not by cost, but by talent. Skilled labor shortages, the report concluded, are the most decisive factor shaping where investment goes from here.
This tracks with broader manufacturing data. The 2025 USA Reshoring Survey, which polled 500 U.S. manufacturers, found that a stronger skilled workforce would bring back significantly more manufacturing than tariffs, a weaker dollar, lower tax rates, or reduced regulation. Manufacturers said they would reshore 30% of their offshored products if the skilled labor existed domestically. A 15% tariff brought back only 23%. A 15% currency drop brought back 21%.
Workforce is the bottleneck. Not policy. Not capital. People.
The National Association of Manufacturers reported in 2025 that 77% of manufacturers struggle to attract and retain a quality workforce. In pharma specifically, the shortage is acute in packaging, quality control, and advanced therapeutics manufacturing, where regulatory complexity demands a skilled and often niche talent pool.
What pharma manufacturing leaders are actually doing in response to this shortage looks less like strategy and more like reflex. Pharmaceutical Executive published an analysis in April 2026 describing what it called the industry hire-train-lose cycle: companies recruit aggressively, train new employees under compressed timelines, and then lose experienced staff to competing facilities offering marginally better packages. The result, according to the publication, is turnover often reported in the low-to-mid teens across biopharma manufacturing roles.
Pharmaceutical Technology’s annual workforce survey, conducted in Q4 2025 and published in early 2026, confirmed the trend. Voluntary turnover among bio/pharma professionals rose from 13.71% in 2024 to 15.91% in 2025. Confidence in the broader industry outlook deteriorated sharply, with the percentage of respondents expecting the industry to improve falling from 43.55% to 22.73% year over year.
The response from most companies has been to hire harder. The problem is that the talent pool everyone is hiring from is the same one. Approximately 60,000 biopharma jobs in the U.S. sit unfilled, according to Actalent’s October 2025 analysis. That represents an 8% industry-wide talent gap, with unemployment among biotech and life sciences professionals at just 3.1%.
You cannot recruit your way out of a structural talent shortage when every competitor is recruiting from the same pool.
McKinsey’s 2025 HR Monitor identified the underlying problem with surgical clarity. Only 12% of U.S. organizations engage in long-term strategic workforce planning. The rest are doing operational workforce planning, which is short-term and forecasts approximately one year ahead. Strategic workforce planning, by contrast, projects staffing needs over a three-to-five-year horizon aligned with business strategy and scenario modeling.
In pharmaceutical manufacturing, where the validation process from capital commitment to first production hire typically runs five to seven years, a one-year workforce horizon is not just inadequate. It is structurally incompatible with the timelines the industry actually operates on.
McKinsey’s earlier joint research with the International Society for Pharmaceutical Engineering surveyed 3,700 respondents at 17 pharmaceutical manufacturers across 28 countries. The findings were striking. More than 80% of pharma manufacturing companies reported a skills mismatch. Only 40% of companies believed they really knew which skills were needed today. Less than 25% believed they knew which skills would be needed in ten years.
This is not an HR problem. It is a forecasting problem at the operations level. And it is being treated as a downstream administrative concern by leaders who would never accept the same lack of rigor in capital planning, supply chain modeling, or facility design.
The workforce challenge is not uniform across pharma manufacturing segments. Different CPHI industries face different versions of the same shortage.
In API and drug substance manufacturing, the reshoring conversation is colliding with a workforce that does not yet exist in the regions where new facilities are being announced. Think Global Health noted in November 2025 that advanced biomanufacturing requires experienced professionals who have spent years in established manufacturing hubs, and many of those hubs are not located near the new construction sites. The result is likely to be significant geographic workforce migration, including from the European Union to the U.S. and across regions within the U.S.
In biologics, the shortage is most acute. The global biologics market is projected to grow 10.5% annually from 2025 to 2035, outpacing traditional pharmaceuticals at 8.7%, per Global Location Strategies. The U.S. accounts for nearly half the global biologics market and houses 90% of the world’s 6,000 FDA-registered biologics facilities. North Carolina workforce development groups estimated 8,000 additional biomanufacturing workers will be needed in the state in 2026 alone.
In CDMO services, the workforce challenge is compounded by the project-based nature of the business. Demand fluctuates with sponsor pipelines, but talent has to be retained through the troughs to be available during the peaks. Most CDMOs do not have the workforce architecture to manage this cycle, and the ones that do treat it as a strategic competitive advantage.
In regulatory and compliance, the shortage is qualitative as much as quantitative. The roles require deep institutional knowledge, and the talent pool of seasoned regulatory affairs leaders is shrinking faster than it is being replenished.
McKinsey’s 2022 analysis of pharma operations strategy concluded that talent shortages cannot be solved by raising wages alone. Long-term reskilling, upskilling, and embedding workforce planning into operations strategy were identified as the structural responses. The firm explicitly noted that only the CEO and head of operations can set the direction, gather the right teams, and manage the interdependencies required.
This is the part most pharma leadership teams have not internalized. Workforce strategy is not delegable to HR. It is an operations C-suite responsibility, with the same level of board attention that capital allocation and supply chain resilience receive.
The CSIS analysis published in February 2026 reached a similar conclusion at the policy level. Tariffs and executive orders, the report concluded, are insufficient on their own to address the workforce challenges facing U.S. pharmaceutical manufacturers. What is needed is a patient, long-term effort of investment and support for workforce development that could achieve the goal of greater reshoring while sustaining U.S. leadership in biomanufacturing.
For individual companies, the implication is concrete. Three questions belong on the next board agenda.
One. Does the company have a workforce plan that matches the time horizon of its capital plan? If the capital plan extends five years and the workforce plan extends one, the capital plan is incomplete.
Two. Is workforce strategy owned by an operations leader with P&L accountability, or is it owned by HR? If it is owned by HR alone, it will be optimized for hiring efficiency rather than for capability building.
Three. Does the company have a partner ecosystem for specialized talent that goes beyond traditional staffing agencies? Generic recruiting models do not solve specialized talent shortages. Companies that win the next decade will be the ones who built the partner relationships before they needed them.
The pharma reshoring story is going to be told two ways over the next ten years.
In one version, the industry built the factories, missed the workforce timing, and watched a generational opportunity for U.S. biomanufacturing leadership erode into a decade of underutilized capacity.
In the other version, the industry treated workforce capability as the strategic constraint it actually is, built the talent infrastructure ahead of the capital infrastructure, and translated $480 billion in commitments into sustained competitive advantage.
Which version gets told depends almost entirely on whether pharma manufacturing leaders are willing to stop treating workforce strategy as an HR matter.
The companies already making that shift are not making it quietly. They are restructuring their operations leadership, investing in long-horizon workforce planning, and building partnerships with specialized search and staffing firms who understand the industry’s regulatory and technical complexity.
The rest are still hiring on twelve-month plans for facilities that take seven years to validate.
The gap between those two groups will define the pharma manufacturing landscape for the next ten years.
RX2 Solutions is a workforce solutions firm specializing in HR outsourcing, executive search, and strategic staffing. We partner with organizations to build high-performing teams through customized talent strategies, leadership placement, and scalable workforce solutions.
📞 Phone: 610.340.3490
📧 Email: info@rx2solutions.com
🌐 Website: www.rx2solutions.com
RX2 Solutions
A Respectfully Professional People Company